|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.
|
23658459 |
2013 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We have compared the cytosolic cath-D level and the amplification of three oncogenes: c-myc, neu-erb-B-2 and int-2 in 140 primary breast carcinomas and 64 axillary lymph nodes collected in 1987 and 1988 at the Cancer Center of Montpellier (Centre Paul Lamarque).
|
2141510 |
1990 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We conclude that, compared to amplification of HER2/NEU, MYC, or INT2 oncogene loci, p53 gene mutations and deletions are the most frequently observed genetic change in breast cancer related to a single gene.
|
1961733 |
1991 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
To attain this goal, amplification of different oncogenes (HER-2/neu, c-MYC and INT-2) was studied in primary tumors of a series of 259 patients with breast cancer (median follow-up of 72 mo).
|
7607564 |
1995 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, to develop a humanized model of MMTV signaling, we over-expressed WNT1 and FGF3 in MCF7 cells, an ER(+) human breast cancer cell line.
|
26421711 |
2015 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This is the first report of an association between amplification of the int-2 oncogene in breast tumours and a significantly increased risk of death from breast cancer, and suggests that int-2 may be useful for identifying breast-cancer patients having a poor prognosis.
|
8449602 |
1993 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Therefore, in this study, locus 11q13 and FGF3 gene (11q13) function were investigated in a radiation and estrogen breast cancer model induced by high-LET (α-particle) radiation and estrogen exposure.
|
25333703 |
2014 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The glutathione S-transferase gene (GST pi) is located on the same chromosome band (11q13) as proto-oncogenes INT2 and HSTF1 which are frequently amplified in breast cancer.
|
1826346 |
1991 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The CCND1-FGF19-FGF4-FGF3 gene cluster in human chromosome 11q13 is amplified in breast cancer, squamous cell carcinoma of head and neck, and bladder tumors, and is also translocated in parathyroid tumors and B-cell lymphoma.
|
12429977 |
2002 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The c-myc, c-erbB-2, hst and int-2 oncogenes are frequently amplified and/or overexpressed in human breast carcinomas.
|
1707153 |
1991 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, these results demonstrated that the peptide FP16, acting as an FGF3 antagonist, is a promising therapeutic agent for the treatment of breast cancer.
|
26323695 |
2015 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Some of these mutations involve amplification of protooncogenes (c-myc, c-erbB-2, and int-2) that have been shown to contribute to experimentally induced breast cancer in mouse model systems.
|
2667653 |
1989 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Sequence analysis of the int-2/fgf-3 gene in aggressive human breast carcinomas.
|
1362493 |
1992 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Patients with INT2/HST1 amplified breast cancer had a significantly shorter disease-free survival compared to those with unamplified genes (P = 0.015, median follow up 45 months).
|
1989653 |
1991 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Other members of the fibroblast growth factor family have been either not expressed in the human breast (FGF3, FGF4) or have been found at much reduced levels in breast cancer (FGF1, FGF2) and this is the first member of the family to potentially influence the progression of breast cancer through stimulation of cell division.
|
9184170 |
1997 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Infrequent (< or =12%) or absent LOH was detected at the remaining loci, including several loci commonly mutated in breast cancer (i.e., INT2, PYGM, and NM23).
|
10619258 |
1999 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In an attempt to probe the significance of HST and INT-2 gene amplification in human breast carcinomas, we have surveyed the amplification status of five molecular markers located on the long arm of chromosome 11 (BCL-1, HST, INT-2 & SEA on 11q13, and ETS-1 on 11q23) in a population of 297 mammary tumors.
|
2181375 |
1990 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genetic alterations have been described in breast carcinomas under the headings of loss of heterozygosity (1p, 3p, 7q, 11p, 17p, 17 and 18q), mutations (p53, c-H-ras-1), and/or gene amplifications (c-myc, int-2/FGF3, and c-erbB-2/neu).
|
7671254 |
1995 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer.
|
9380415 |
1997 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.
|
21936542 |
2011 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Analysis of the int-1, int-2, c-myc, and neu oncogenes in human breast carcinomas.
|
1975511 |
1990 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Amplification of the proto-oncogenes int-2, c-erb B-2 and c-myc in human breast cancer.
|
2611995 |
1989 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Amplification and expression of these genes is particularly interesting in the context of oncovirus involvement, because INT2 is a homolog of mouse int2 which causes mammary carcinoma in mice when activated by integration of retrovirus mouse mammary tumor virus.
|
10786811 |
2000 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
After a median follow-up period of 66 months, CCND1 or INT-2 amplification was not associated with significant increases in relapse or death from breast cancer.
|
9816285 |
1996 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A rapid, non-radioactive approach based on qdPCR and fluorescent DNA technique was applied for determination of int-2 and c-erbB2 gene amplification and correlated with other prognostic factors in 70 breast cancer samples.
|
9329619 |
1997 |